Kyverna Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing cell therapies for patients suffering from B cell-driven autoimmune diseases. The company pioneers next-generation chimeric antigen receptor (CAR) T-cell therapies designed to deeply deplete B cells, reset the immune system, and promote long-lasting, treatment-free remission. Its lead therapeutic candidate, mivocabtagene (miv-cel, KYV-101), is currently advancing through clinical trials for various rheumatology and neurology indications, including lupus nephritis, systemic sclerosis, multiple sclerosis, myasthenia gravis, and stiff person syndrome.
